Microbiome and chronic inflammatory bowel diseases.

Area of Science:

• Gastroenterology and Immunology
• Microbiome Research
• Inflammatory Bowel Diseases (IBD)

Background:

• The microbiome is increasingly recognized as a central driver of chronic inflammatory bowel diseases (IBD).
• Both human patient data and rodent models indicate a significant role for gut microbiota in IBD pathogenesis.
• Complex interactions between the microbiome, host genetics, environmental factors, and host defense molecules like antimicrobial peptides are implicated in IBD.

Purpose of the Study:

• To provide a comprehensive overview of the current understanding of the microbiome's role in IBD.
• To discuss the interplay between antimicrobial peptides, barrier defects, and microbial composition in IBD.
• To explore future therapeutic strategies for IBD that extend beyond conventional anti-inflammatory treatments.

Main Methods:

• This review synthesizes findings from existing human and animal studies on the gut microbiome and IBD.
• It examines the impact of antimicrobial peptides and host defense mechanisms on the microbiome in the context of IBD.
• The review analyzes the microbial-mucosal interface and its alterations in IBD.

Main Results:

• Evidence strongly supports the microbiome as a critical factor in the development and progression of IBD.
• Antimicrobial peptide dysregulation and barrier defects are consistently observed in IBD, influencing microbiome composition.
• The microbial-mucosal interface is significantly impacted by these host-microbe interactions in IBD.

Conclusions:

• A holistic view of the microbiome-host interaction is crucial for understanding IBD.
• Targeting the microbiome and host defense mechanisms offers promising avenues for novel IBD therapies.
• Future IBD treatments may involve modulating the microbiome and enhancing host defense beyond anti-inflammatory approaches.